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 INTRODUCTION 
           India is frequently referred to as the diabetic capital of the world. 
Diabetes mellitus is widely prevalent in our country and its incidence is rising 
in alarming proportions. The worldwide prevalence of diabetes has risen 
dramatically over past two decades, from an estimated 30 million cases in 
1985 to 177 million in 2000. Based on current trends, more than 360 million 
individuals world wide will have diabetes by the year 2030. Although the 
prevalence of both type 1 and type 2 diabetes is increasing worldwide, the 
prevalence of type 2 diabetes is rising much more rapidly because of 
increasing obesity and reduced activity levels as countries become more 
industrialized. Worldwide estimates project that in 2030 the greatest number 
of individuals with diabetes will be 45-64 years of age. 
                 According to the Diabetes Atlas published by the International 
Diabetes Federation, there are an estimated 40 million persons with diabetes 
in India in 2007 and this number is predicted to rise to almost 70 million 
people in 2025 by which time every fifth diabetic subject in the world would 
be an Indian. Diabetes is a major cause of mortality, but several studies 
indicate that diabetes is likely underreported as a cause of death. A recent 
estimate suggested that diabetes was the fifth leading cause of death 
 worldwide and was responsible for almost 3 million deaths annually (1.7-
5.2% of deaths worldwide). 
             The real burden of the disease is however due to its micro and macro 
vascular complications which lead to increased morbidity and mortality. 
Diabetic autonomic neuropathy is a serious and common complication of 
diabetes. Despite its relationship to an increased risk of cardiovascular 
mortality and its association with multiple symptoms and impairments, the 
significance of diabetic autonomic neuropathy has not been fully appreciated. 
Diabetic autonomic neuropathy frequently co-exists with other peripheral 
neuropathies and other diabetic complications. 
           Most serious consequences of autonomic neuropathy have been due to 
cardiac sympathetic and para sympathetic denervation and prolongation of 
QTc interval which may lead to arrhythmias, silent cardiac ischemia, and 
abnormal response to hypoxia during surgical procedures and anesthesia. 
        Cardiovascular autonomic neuropathy is the most studied and clinically 
important form of diabetic autonomic neuropathy. Determination of the 
presence of cardiac autonomic neuropathy is usually based on a battery of 
autonomic function tests rather than just one test. Other forms of autonomic 
neuropathy can be evaluated with specialized tests but these are less 
standardized and less available. 
       REVIEW OF LITERATURE 
DIABETES MELLITUS 
          Diabetes mellitus (DM) refers to a group of metabolic disorders which 
have common denominator namely hyperglycemia. Factors contributing to 
hyperglycemia include reduced insulin secretion, decreased glucose 
utilization and increased glucose production.  The metabolic deregulation 
associated with DM causes secondary pathophysiologic changes in multiple 
organ systems that impose a tremendous burden on the individual with 
diabetes and on the health care system. 
CLASSIFICATION 
           DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia. The two broad categories of DM are designated type 1&     
type 2. 
 -       Type 1 is the result of complete or near-total insulin deficiency. 
 -   Type 2 DM is a heterogeneous group of disorders characterized by 
variable degree of insulin resistance, impaired insulin secretion, and 
increased glucose production. Type 2 DM is preceded by a period of 
abnormal glucose homeostasis classified as impaired fasting glucose (IFG) 
impaired glucose tolerance (IGT). 
 ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS 
I  Type 1 diabetes (beta-cell destruction, usually leading to absolute insulin 
deficiency)  
A. Immune-mediated 
B. Idiopathic 
II  Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretary defect with 
insulin resistance). 
III  Other specific types of diabetes. 
A. Genetic defects of beta cell function characterized by 
mutations in  
1. Hepatocyte nuclear transcription factor (HNF) 4  
 (MODY 1) 
2. Glucokinase (MODY 2) 
3. HNF-1(MODY 3) 
4. Insulin promoter factor -1 (IPF-1;MODY 4) 
5. HNF -1 (MODY 5) 
6. NeuroD1 (MODY 6) 
7. Mitochondrial DNA  
8. Subunits of ATP- sensitive potassium channel  
9. Proinsulin or insulin conversion  
            B.  Genetic defects in insulin action 
1. Type A insulin resistance  
2. Leprechaunism 
3. Rabson- mendenhall syndrome 
4. Lipodystrophy syndrome  
C.    Diseases of the exocrine pancreas-pancreatitis, pancreatectomy, 
neoplasia, cysticfibrosis, hemochromatosis, fibrocalculous 
pancreatopathy, mutations in carboxyl ester lipase. 
D.Endocrinopathies- Acromegaly, Cushing’s Syndrome, 
Glucagonoma, Phenochromocytoma, Hyperthyroidism, 
Somatostatinoma, Aldosteronoma. 
E.Drug-or chemical induced-vacor , pentamidine  nicotinic acid , 
glucocorticoids, thyroid hormone, diazoid, beta-adrenergic agonists, 
thiazides, phenytoin, protease inhibitors, clozapine. 
F.Infections –congenital rubella, cytomegalovirus, coxsackie 
G.Uncommon forms of immune mediate diabetes-“stiff-person” 
syndrome, anti insulin  receptor antibodies  
H.Other gentic syndromes sometimes associated with diabetes :  
 Down Syndrome, Klinefelter’sSyndrome, TurnersSyndrome’ 
Wolframs’syndrome Friedreich’s Ataxia, Hunington’sChorea,Laurence 
Moon Biedl Syndrome,Myotonic Dystrophy, Porphyria, Prader –Willi 
Syndrome. 
IV. Gestational diabetes mellitus(GDM) 
          Glucose intolerance may develop during pregnancy. Insulin resistance 
is related to the metabolic changes of late pregnancy and the increased insulin 
requirements may lead to IGT. GDM occurs in 4% of pregnancies in the 
United states. Most women revert to normal glucose tolerance post-partum 
but have a substantial risk (30-60%) of developing DM later  in life.  
Diagnosis of diabetes mellitus 
                  The national diabetes data group and World Health Organization 
(WHO)  have issued  certain diagnostic criteria: 
• Symptoms of diabetes plus random blood glucose concentration 
11.1mmol/L (200mg /dL)aor 
• Fasting plasma glucose 7.0 mmol/L(126 mg/dL)b or 
• Two –hour plasma glucose 11.1 mol/L(200mg/dL) during an 
oral glucose tolerance test.c 
aRandom is defined as without regard to time since last time meal . 
bFasting is defined as no caloric intake for at least 8 hours. 
                  cThe test should be performed using a glucose load containing the 
equivalent of 75 gms anhydrous glucose dissolved in water ; not 
recommended for routine clinical use. 
Glucose tolerance is classified into three categories based on the FPG: 
(1)   FPG<5.6mmol/L(100-125mg/dL) is considered normal 
(2)   FPG=5.6-6.9mmol/L(100-125mg/dL)is defined as IFG 
(3)   FPG=7.0mmol/L(126mg/dL) warrants the diagnosis of DM. 
 Based on the OGTT,IGT is defined a plasma glucose 
levels between 7.8 ad 11.1 mmol/L (140 and199 mg/dL)and diabetes is 
defined as a glucose >11.1 mmol/L (200mg/dL)2 h after a 75-g oral glucose 
load. Some individuals have both IFG and IFG and IGT individuals with IFG 
and/or IGT . Recently designated ‘pre –diabetes ’ by the American Diabetes 
association (ADA) are at  substantial risk for developing type 2DM (25-40% 
risk over the next 5 years) and have an increased risk of cardiovascular 
disease.2 
 
 
 
 Risk factors for type 2 diabetes mellitus 
1. Family history of diabetes (i.e, parent or sibling with type 2 diabetes) 
2. Obesity (BMI>25kg/m2) 
3. Habitual physical inactivity 
4. Race/ethnicity(e.g.,African, American, Latino, NativeAmerican, Asian 
American, Pacific Islander) 
5. Previously identified IFG or IGT 
6. History of GDM or delivery of  baby>4 kg(>9lb) 
7. Hypertension (blood pressure>140/90mmHg) 
8. HDL cholesterol level <35 mg/dL(0.90mmol/L) and/or a triglyceride 
level >250mg/dL (2.82mmol/L) 
9. Polycystic ovary syndrome or acanthosis nigricans 
10. History of vascular disease  
    Pathophysiology 
 Type 2 DM is characterized by impaired insulin 
secretion, insulin resistance, excessive hepatic glucose production, and 
abnormal fat metabolism. Obesity ,particularly visceral or central (as 
evidenced by the hip-waist ratio), is very common in type 2DM in the 
early stages of the disorder .Glucose tolerance remains near-normal, 
despite insulin resistance , because the pancreatic beta cells compensate 
 by increasing insulin output. As insulin resistance and compensatory 
hyperinsulinemia progress, the pancreatic islets in certain individuals are 
unable to sustain the hyperinsulinemic state IGT, characterized by 
elevations in postprandial glucose, then develops. A further decline in 
insulin secretion and an increase in hepatic glucose production lead to 
overt diabetes with fasting hyperglycemia. Ultimately  Beta cells failure 
may ensure. 
COMPLICATION  OF  DM 
Acute Complications: 
                          Diabetic ketoacidosis (DKA) and Hyperglycemic 
Hyperosmolar State (HHS) are acute complications of diabetes1.DKA is 
primarily seen in patients with type 1 DM, and HHS is seen in patients with 
type 2DM.Both disorders are associated with  absolute and relative insulin 
deficiency, volume depletion, and altered mental status. Both are associated 
with potentially serious complications if not promptly diagnosed and 
treated1,2 
Chronic complications: 
                 Chronic complications of DM affect many organ systems and are 
responsible for majority of morbidity and mortality. 
 Microvascular 
Eye disease: Retinopathy 
                     Macular edema 
                    Cataract 
                    Glaucoma 
Neuropathy: 
sensory  and motor 
                    Autonomic 
Nephropathy  
Macrovascular 
                   Coronary artery disease 
                    Peripheral vascular disease 
                   Cerebrovascular disease 
Others  
                    Gastrointestinal 
                    Genitourinary 
                    Dermatological 
    The risk of complications of type 1 and type 2 
increase as a function of the duration of hyperglycemia .They usually become 
apparent in the second decade of hyperglycemia.1,2 
MECHANISM OF COMPLICATIONS 
                        Three major theories have been proposed to explain the 
emergence of complications.2,1 
1.   Increased intracellular glucose leads to the formation of advanced 
glycosylation end products (AGEs) via non enzymatic glycosylation of 
cellular proteins. AGEs have been shown to cross link proteins, accelerate 
atherosclerosis, promote glomerular dysfunction, reduce nitric oxide 
synthesis, induce endothelial dysfunction and alter the extra cellular matrix 
composition and structure. 
2.  Hyperglycemia increases glucose metabolism by sorbitol pathway. 
Increased intracellular glucose is converted to sorbitol by the enzyme aldose 
reductase.Increased sorbitol concentration affect several aspects of cellular 
physiology and may lead to cellular dysfunction. 
3.   Hyperglycemia increases the formation of diacyl glycerol leading to 
activation of certain isoforms of protein kinase which in turn ,affect a variety 
of cellular events that leads to diabetes mellitus related complications . 
 Finally, oxidative stress and free radical generation may also promote the 
development of complications 
DIABETIC RETINOPATHY 
       Diabetic retinopathy is the most common cause of blindness in adults. 
Hyperglycemia increases retinal blood flow and metabolism and has direct 
effect on retinal endothelial cells and pericytes, loss of which impairs 
vascular autoregulation. The resulting uncontrolled blood flow increases 
production of vasoactive substances  and endothelial proliferations resulting 
in capillary closure. This causes chronic retinal hypoxia and stimulates 
production growth factors, including  vascular endothelial growth 
factor(VEGF) to stimulate endothelial cell growth  causing new vessel 
formation and increased vascular permeability causing exudative damage. 
       Diabetic retinopathy includes microaneurysms, intraretinal hemorrhage, 
exudates, macular edema, macular ischemia, neovascularization, vitreous 
hemorrhage, and traction retinal detachment. Symptoms may not develop 
until late in the disease. The degree of retinopathy is highly correlated with, 
duration of diabetes, blood glucose levels, blood pressure. 
 
 
 Pathophysiology. 
Nonproliferative Retinopathy:  (also called background retinopathy) 
develops first and causes increased capillary permeability, micro aneurysms, 
hemorrhages, exudates, macular ischemia, and macular edema (thickening of 
the retina caused by fluid leakage from capillaries). 
Proliferative retinopathy: develops after nonproliferative retinopathy and is 
more severe; it may lead to vitreous hemorrhage and traction retinal 
detachment. Proliferative retinopathy is characterized by abnormal new 
vessel formation (neovascularization), which occurs on the inner (vitreous) 
surface of the retina and may extend into the vitreous cavity and cause 
vitreous hemorrhage. The neovascularization is often accompanied by 
preretinal fibrous tissue, which, along with the vitreous humor, can contract, 
resulting in a traction retinal detachment. Neovascularization may also occur 
in the anterior segment of the eye on the iris, which can result in neovascular 
membrane growth in the angle of the eye at the peripheral margin of the iris, 
leading to neovascular glaucoma. Vision loss with proliferative retinopathy 
may be severe. 
Clinically significant macular edema can occur with nonproliferative 
or proliferative retinopathy and is the most common cause of vision loss due 
to diabetic retinopathy. 
 Symptoms and Signs 
Nonproliferative Retinopathy: Vision symptoms accompany macular 
edema or macular ischemia. However, patients may be unaware of vision 
loss. The first signs of nonproliferative retinopathy are 
• Capillary micro aneurysms 
• Dot and blot retinal hemorrhages 
• Hard exudates 
• Cotton-wool spots (soft exudates) 
                      Cotton-wool spots are areas of micro infarction that lead to 
retinal opacification; they are fuzzy-edged and white and obscure underlying 
vessels. Hard exudates are discrete, yellow, and generally deeper than retinal 
vessels and suggest retinal edema. 
Signs in later stages are macular edema (seen on slit-lamp biomicroscopy as 
elevation and blurring of retinal layers), Venous dilation and intraretinal 
microvascular abnormalities. 
Proliferative Retinopathy: Symptoms may include blurred vision, black 
spots or flashing lights in the field of vision, and sudden, severe painless 
vision loss. Some of these symptoms may be caused by vitreous hemorrhage 
or traction retinal detachment. 
 Proliferative retinopathy, unlike nonproliferative retinopathy, causes 
fine preretinal capillaries (newly developed capillaries) to appear on the optic 
nerve or retinal surface. Macular edema or retinal hemorrhage may be visible 
on funduscopy.  
Diagnosis is by funduscopy; further details are elucidated by 
fluorescein angiography and optical coherence tomography. Treatment 
includes control of diabetes and BP and ocular laser photocoagulation, 
intravitreal injection of drugs, vitrectomy, or a combination. 
DIABETIC NEPHROPATHY 
                            Diabetic nephropathy is the leading cause of end stage renal 
disease in many countries. 
Mechanism of  hyperglycemia to ESRD  involve  
1. Interaction of soluble factors (AT II,AGEs, Endothelin) 
2. Hemodynamic alterations in renal microcirculation. 
3.       Structural charges in glomerulus    
DIABETIC NEUROPATHY 
     “A descriptive term meaning a demonstrable disorder, either clinically 
evident or subclinical, that occurs in the setting of diabetes mellitus without 
other causes for peripheral neuropathy. The neuropathic includes 
manifestations in the somatic and autonomic parts of the peripheral nervous 
system. 
 AETIOPATHOGENESIS 
Hypotheses concerning the multiple etiologies of diabetic neuropathy 
include a metabolic insult to nerve fibres, neurovascular insufficiency, 
autoimmune damage, and neurohormonal growth factor deficiency. Several 
different factors have been implicated in this pathogenic process. 
Hyperglycemic activation of the polyol pathway leading to accumulation of 
sorbitol  and potential changes in the NAD:NADH ratio may cause direct 
neuronal damage and/or decreased nerve blood flow(Greene et al,1983). 
Activation of protein kinase C includes vasoconstriction and reduces 
neuronal blood flow(Verves et al,2001) increased oxidative stress, with 
increased free radical production, causes vascular endothelium damage and 
reduces nitric oxide bioavailability(Cameron et al.1997) Alternatively, excess 
nitric oxide production may result in formation of peroxynitrate and damage 
endothelium and neurons, a process referred to as nitrosative stress. In a 
subpopulation of individuals with neuropathy, immune mechanism may also 
be involved. Reduction in neurotropic growth factors, deficiency of essential 
fatty acids, and formation of advanced glycosylation end products (localized 
in endoneurial blood vessels(Brownlee,1992) also result in reduced 
endoneurial blood flow and nerve hypoxia with altered nerve function. The 
result of this multifactorial process may be activation of genes involved in 
neuronal damage. 
 DIABETIC AUTONOMIC NEUROPATHY 
                 A subtype of the peripheral polyneuropathies that accompany 
diabetes, diabetic autonomic neuropathy can involve the entire autonomic 
nervous system(ANS).Diabetic autonomic neuropathy may be either 
clinically evident or subclinical. It is manifested by dysfunction of one more 
organ systems (eg: Cardiovascular, Git, Genitourinary, Sudomotor, or 
Ocular). Indeed ,because the vagus nerve (the longest of the ANS nerves, 
accounts 75% of the all parasympathetic activity),and the diabetic autonomic 
neuropathy manifests in longer nerves. Symptoms suggestive of autonomic 
dysfunction may be common, they may frequently be due to other causes 
rather than to true autonomic neuropathy. Subclinical autonomic dysfunction 
can ,however occur within a year of diagnosis of type 2 diabetes 
patients(Pfeier et al,1984).Because of its association with a variety of adverse 
outcomes including cardiovascular deaths, cardiovascular autonomic 
neuropathy(CAN) is the most clinically important and well studied form of 
diabetic autonomic neuropathy. 
 
 
 
 EPIDEMIOLOGY 
             The reported prevalence of diabetic autonomic neuropathy varies, 
depending on whether studies have been carried out in  community, clinic, or 
tertiary referral center .In a community based population study of diabetic 
neuropathy in Oxford, the prevalence of autonomic neuropathy as defined by 
one or more abnormal heart rate variability(HRV) test result was 16.7%.(Neil 
et al.). 
            In a further study, Ziegler(18) et al evaluated the prevalence of CAN in 
1,171 diabetic patient(647 type 1 diabetes patients,524 type 2 diabetes) 
randomly recruited from 22 diabetes centres in Germany, Austria and 
Switzerland. The study found that 25.3% of patients with type 1 diabetes and 
34.3% of patients with type 2 diabetes had abnormal findings in more than 
two of six autonomic function tests(Zieglar,19929).Vernotti rt al. found that 
47 out of 110 diabetic children and adolescents showed one or more 
abnormal test for cardiac autonomic dysfunction.(Ziegler9 et al.1992).Verotti 
et al found that 47of 110 diabetic children and adolescents showed one or 
more abnormal test for cardiac autonomic  dysfunction. Overt signs and 
symptoms of autonomic disease fall in to one or more of the following 
categories. 
 
 Cardiovascular 
• Resting tachycardia 
• Exercise intolerance 
• Orthostatic hypotension 
• Silent myocardial infarction 
Gastrointestinal 
• Esophageal dysmotility 
• Gastroparesis diabeticorum 
• Constipation 
• Diarrhea 
• Fecal incontinence 
Genitourinary 
• bladder(diabetic cystopathy) 
• Erectile dysfunction 
• Retrograde ejaculation 
• Female sexual dysfunction(eg: loss of vaginal lubrication) 
Metabolic 
• Hypoglycemia unawareness 
• Hypoglycemia associated autonomic failure 
 Sudomotor 
• Anhidrosis 
• Heat intolerance 
• Gustatory sweating 
• Dry skin  
Pupillary 
• Pupillomotor function impairment(eg: decreased diameter of dark 
adapted pupil) 
• Argyll Robertson pupil  
CARDIAC AUTONOMIC NEUROPATHY 
Cardiovascular autonomic neuropathy (CAN), a common form of 
autonomic dysfunction found in patients with diabetes mellitus, causes 
abnormalities in heart rate control, as well as defects in central and peripheral 
vascular dynamics. Individuals with parasympathetic dysfunction have a high 
resting heart rate most likely because of vagal neuropathy that results in 
unopposed increased sympathetic outflow. Persons with a combined 
parasympathetic/sympathetic dysfunction have slower heart rates. With 
advanced nerve dysfunction, heart rate is fixed. Thus, it is apparent that the 
determination of heart rate itself is not a reliable diagnostic sign of CAN. 
Reduction in variability of heart rate is the earliest indicator of CAN. Clinical 
 manifestations of CAN include exercise intolerance, intraoperative 
cardiovascular lability, orthostatic hypotension (OH), asymptomatic 
ischemia, painless myocardial infarction (MI), and increased risk of mortality 
An increased resting heart rate has frequently been observed in diabetic 
patients. With progression of disease, some patients display a fixed heart rate 
that responds only minimally to physiologic stimuli. 
Orthostatic hypotension occurs in diabetes mellitus as a consequence of  
efferent sympathetic vasoconstriction of the splanchnic and other vascular 
beds(Helsted et al 1981) 
                      Other CVS abnormalities have included a cardiomyopathy in 
patients without ischemic heart disease manifesting as impaired myocardial 
contractility and decreased left ventricular diastolic  filling observed by radio 
nuclear ventriculography. Silent cardiac ischemia and prolongation of QT has 
been observed.(Kahn et al 1987) 
                          There is increased frequency of sudden death in patients with 
autonomic neuropathy . Proposed etiologies include cardio respiratory arrest 
caused by cardiac arrhythmias, silent cardiac ischemia, sleep apnoea, and a 
with an  abnormal response to hypoxia, particularly in pulmonary 
infections.(Page et al 1978). Abnormal measures of cardiac autonomic 
function also have correlated with abnormal autonomic functions in other 
 organ systems including abnormal pupillomotor, gastrointestinal infections. 
Ewings(4) et al reported a 2.5 –year mortality rate of 27.5% that increased to 
53%after 5 years in diabetic patients with abnormal autonomic function tests 
,compared with a mortality of only 15% over the 5 year period among 
diabetic patients with normal autonomic function tests(Ewings(4) et al 1980) 
CLINICAL MANIFESTATIONS OF CARDIOVASCULAR 
AUTONOMIC DYSFUNCTION 
Exercise intolerance 
In diabetic individuals with CAN, exercise tolerance is limited as a 
result of impaired parasympathetic/sympathetic responses that would 
normally enhance cardiac output and result in directing peripheral blood flow 
to skeletal muscles . Reduced ejection fraction, systolic dysfunction, and 
decreased diastolic filling, potentially as a result of CAN, also limit exercise 
tolerance 
Intraoperative cardiovascular lability. 
There is a 2- to 3-fold increase in cardiovascular morbidity and 
mortality intra operatively for patients with diabetes (19).Studies have 
demonstrated that the induction of anesthesia causes greater degree of decline 
in heart rate and blood pressure in diabetic patients compared with non 
 diabetic individuals (20)and that hemodynamic stability, in the intraoperative 
period, depends on the severity of autonomic dysfunction (21). Patients with 
severe autonomic dysfunction have a high risk of blood pressure instability 
(21, 22), and intraoperative blood pressure support is needed more often in those 
with greater impairment(20). Intraoperative hypothermia (23), which may 
decrease drug metabolism and affect wound healing, and impaired hypoxic-
induced ventilatory drive (24) have also been shown to be associated with the 
presence of CAN. 
Orthostatic hypotension 
A change from lying to standing normally results in activation of a 
baroreceptor-initiated, centrally mediated sympathetic reflex, resulting in an 
increase in peripheral vascular resistance and cardiac acceleration (19). OH is 
characterized by a defect in this reflex arc, resulting in signs and symptoms 
such as weakness, faintness, dizziness, visual impairment, and syncope 
.Although the absolute fall in blood pressure is arbitrary, OH is usually 
defined as a fall in blood pressure [i.e.>20–30mm Hg for systolic or >10 mm 
Hg for diastolic (26, 27)] in response to postural change, from supine to 
standing. 
 
 Painless myocardial ischemia 
Inability to detect ischemic pain can impair the recognition of 
myocardial ischemia or MI. The mechanisms of painless myocardial ischemia 
are, however, complex and not fully understood. Altered pain thresholds, sub 
threshold ischemia not sufficient to induce pain, and dysfunction of the 
afferent cardiac autonomic nerve fibers have all been suggested as possible 
mechanisms (28).A recent investigation that used positron emission 
tomography to measure regional cerebral blood flow as an index of regional 
neuronal activation has shown that impaired afferent signaling resulting from 
autonomic dysfunction is associated with failed signal transmission from the 
thalamus to the frontal cortex(29) A meta-analysis of 12 studies also 
demonstrated a consistent association between CAN and the presence of 
painless myocardial ischemia12. The Mantel-Haenszel estimate for the pooled 
prevalence rate risk for silent myocardial ischemia was 1.96, with a 95% 
confidence interval of 1.53–2.51 (P < 0.001; n = 1468 total subjects) (12). 
Thus, patients with CAN warrant more careful attention. Cardiovascular 
autonomic function testing may be an important component in the risk 
assessment of diabetic patients with coronary artery disease (21).  
 
 Increased risk of mortality 
Impaired autonomic control of heart rate is linked to increased risk of 
mortality. Reduced parasympathetic function or increased sympathetic 
activity may provide the propensity for lethal arrhythmias (32) 
Treatment interventions :non pharmacological methods: 
  Nonpharmacological measures, such as increasing consumption of 
water 95) and wearing lower-extremity stockings, can be used to reduce 
symptoms (e.g. dizziness, dyspnea) (96).It is well known that exercise plays an 
important role in the treatment of diabetes. The role of exercise in the 
improvement of cardiovascular autonomic function is not as clear. Numerous 
studies both in diabetic and non diabetic populations have tried to determine 
whether HRV can be improved by exercise. For example, chronic endurance 
exercise training in sedentary adult males (81) and a single bout of submaximal 
endurance exercise in healthy males (82) were associated with increased HRV 
with a shift toward parasympathetic influence on cardiovascular function. 
Endurance training was also shown to improve vagal activity in non diabetic 
patients who had a MI (83) and in insulin-requiring diabetic individuals with 
early CAN (84). Other studies showed no benefit or only minimal benefit for 
healthy men (85) and individuals with type 2 diabetes (86). The discordant 
findings are most likely due to differences in patient populations, lack of 
 randomization, differences in length and type of exercise, and various 
measurements of autonomic function. Thus, more intervention studies are 
needed to determine the best exercise protocol that results in improved 
autonomic function for diabetic persons with CAN. In addition, it will be 
important to evaluate whether beneficial effects in autonomic function result 
in favorable effects on the clinical outcome (e.g. better exercise tolerance, 
decreased mortality) of these patients. 
Treatment interventions :pharmacological agents: 
 Interventions to ameliorate reduced HRV are being evaluated in 
clinical trials based on theories of the pathogenesis of diabetic neuropathy. 
Development of diabetic neuropathy is the result of a multifactorial process 
including metabolic insult to nerve fibers, neurovascular insufficiency, 
increased oxidative stress, reduction in neurotropic growth factors, deficiency 
of essential fatty acids, formation of advanced glycosylation end products, 
and autoimmune damage (12). When treating OH due to autonomic 
dysfunction, pharmacological therapies must balance an increase in standing 
blood pressure against prevention of supine hypertension (96). In addition, OH 
can be aggravated by different forms of therapy [e.g. tricyclic antidepressant 
(amitriptyline)] used for the treatment of other complications (e.g. painful 
 sensory neuropathy). Therefore, careful attention to other medications that 
may aggravate OH in these patients is necessary (97).  
  Various pharmacological agents that are directed at components of the 
pathogenic process are described below. 
Glycemic control 
The results of the Diabetes Control and Complications Trial showed 
that intensive treatment prevented the development of abnormal RR variation 
and slowed the deterioration of autonomic dysfunction over time (39). 
Eighteen years of follow-up of a group of type 1 diabetic individuals 
demonstrated that fair long-term glycemic control (i.e. glycosylated 
hemoglobin <8.4%) was associated with preserved cardiovascular autonomic 
function, whereas lack of fair glycemic control was associated with 
dysfunction (40). For persons with type 2 diabetes, intensive insulin therapy 
showed a small tendency for improved autonomic function, whereas 
deterioration was noted in the conventionally treated group (41). 
Antioxidants 
During chronic hyperglycemia, the metabolism of glucose also results 
in the generation of free radicals. Although free radicals of superoxide and 
hydrogen peroxide are essential for normal cell function, excessive 
 accumulation of free radicals is detrimental and has a direct neurotoxic effect 
(42). α -Lipoic acid, an antioxidant that reduces free radical formation, 
appears to slow progression of CAN (43, 44). For persons with type 2 diabetes, 
the improvement in CAN was seen after 4 months of treatment with an oral 
dosage of 800 mg/d (44). For persons with type 1 diabetes, the effect on 
autonomic function was seen after 10 d of 600 mg daily iv α -lipoic acid 
followed by 600 mg given orally for 50 d (43).It should be noted that many 
herbal manufacturers are promoting α -lipoic acid for use by patients with 
diabetes, but studies evaluating the effectiveness of these products have not 
been performed. Vitamin E has been shown to improve the ratio of cardiac 
sympathetic to parasympathetic tone for persons with type 2 diabetes (45). In 
light of a recent meta-analysis that found that 400 IU/d or more may increase 
all-cause mortality, high doses of vitamin E should be avoided (46). 
Angiotensin converting enzyme (ACE) inhibitors 
Micro vascular insufficiency has also been proposed as a potential 
component in the pathogenesis of diabetic neuropathy. Results of animal 
studies have suggested that impaired ganglion blood flow in diabetes could 
be responsible for neuro degenerative changes in autonomic postganglionic 
cell bodies .47 In human diabetic neuropathy, impaired nerve blood flow has 
 been demonstrated(48). Given that vascular dysfunction may be part of the 
pathogenesis of diabetic neuropathy, ameliorating this abnormality may 
positively benefit nerve function. ACE inhibitors promote vasodilation by 
preventing the generation of angiotensin II and by preventing the breakdown 
of bradykinin. Angiotensin II, in addition to its role as a vasoconstrictor, 
stimulates aldosterone release and promotes sympathetic outflow, thus ACE 
inhibitors may provide additional benefits as a result of the inhibition of 
angiotensin-II. With regard to changes in HRV, the use of ACE inhibitors in 
patients with CAN has resulted in conflicting outcomes. Of the ACE 
inhibitors studied, 12 months of use of quinapril showed some degree of 
success in treating CAN (49), whereas no improvement of cardiovascular 
autonomic function was shown after 12 months of treatment with trandolapril 
(50). Conflicting results from various studies are disappointing, but it is 
important to remember that the effect of medications might not be 
homogeneous, even within the same class, and the beneficial response of an 
ACE inhibitor may depend on the degree of tissue penetration (51). 
Angiotensin type 1 blockers 
Angiotensin type 1 (AT1) receptor mediates all potentially deleterious 
effects of angiotensin II (52). AT1 antagonists block the AT1receptor, thus 
blocking the harmful effects of angiotensin II. Raelene(3) et al conducted a 1-
 yr clinical trial in 44 diabetic individuals to determine the effect of losartan 
on HRV. Raelene et al(3)  hypothesized that losartan would improve nerve 
function by increased nerve blood flow and inhibition of angiotensin II-
induced facilitation of sympathetic neuro transmission. Although 50 mg of 
losartan  appeared to slow the expected decline in RR variation, there was no 
significant improvement (53). Improved cardiovascular autonomic function 
was, however, shown in another study, in which 23 diabetic individuals were 
treated with 100 mg of losartan for 1 year (54). Twelve weeks of treatment of 
losartan (50–100mg/d) was also shown to reduce muscle sympathetic activity 
and improve cardiac baroreceptor sensitivity for 10 non  diabetic males with 
hypertension (55). In contrast, a 7-d trial in non diabetic males treated with 
eprosartan was shown to lower HRV (56). 
Aldosterone blockers 
Aldosterone has been shown to affect the autonomic nervous system 
with sympathetic activation and parasympathetic inhibition (57)and impair the 
baro reflex response (58). Other dysfunctions associated with aldosterone 
include the blockage of myocardial uptake of norepinephrine in animal 
models (59) and decreased arterial and venous compliance, leading to vascular 
organ damage(60). Spironolactone, an aldosterone-receptor blocker, has been 
used to reduce the morbidity and mortality for patients with severe heart 
 failure (57). Mechanisms thought to promote the beneficial effect of 
spironolactone include blocking the effect of aldosterone on the loss of 
potassium and magnesium and improved HRV (61, 62, 63). For example, acute 
administration of an aldosterone antagonist given iv has been shown to 
improve HRV and baroreflex sensitivity in healthy subjects, suggesting that 
aldosterone exerts a tonic inhibitory effect on cardiac vagal control (64).In 
disease-specific studies, the use of spironolactone improved HRV and 
survival for patients with congestive heart failure(61, 62, 63). In contrast, 
however, one study of individuals with type 2 diabetes administered 
spironolactone 50 mg/d for1 month demonstrated a small but significant 
worsening in HRV(65). It is possible that the effects of spironolactone maybe 
disease specific.  
Calcium-channel blockers 
Calcium-channel blockers prevent the flow of calcium ions into 
cardiovascular cells by binding to the 1 subunit of the L-type voltage-gated 
calcium channel (66). The drug class is heterogeneous, however, with reflex 
sympathetic activation after blood pressure reduction occurring more 
frequently after blockade with dihydropyridines than phenylalkylamines (66). 
In studies of hypertensive individuals, verapamil depressed sympathetic 
activity (66), and slow release diltiazem had favorable effects on autonomic 
 function (67).Verapamil also decreased norepinephrine excretion in persons 
with stable angina pectoris (68) and improved parasympathetic function in non 
diabetic patients after an acute MI (69). Although the mechanism by which 
verapamil influences HRV is not clear  ,it may be due to specific properties 
of the drug that have a suppressive effect on sympathetic outflow of 
catecholamines(69). Calcium-channel blockers may not, however, have a 
beneficial effect on HRV in persons with diabetes. For example, verapamil 
had no effect on HRV in diabetic subjects post-MI (69), where as long-acting 
calcium antagonists enhanced, rather than reduced, sympathetic activity in 
patients with type 2 diabetes (70). 
ß-Blockers 
The use of ß-blockers in diabetic patients has been questioned because 
these agents may mask signs and symptoms of hypoglycemia and interfere 
with insulin release. Nonetheless, in the Cooperative Cardiovascular Project, 
post-MI diabetic patients treated with ß-blockers had a 36% reduction in 
mortality (71). In addition, ß-blockers were associated with a lower 1-yr 
mortality rate for elderly diabetic patients(72). The exact reason for the 
reduction in mortality may or  may not be related to the effect on CAN. In the 
ß-blocker Heart Attack Trial, propranolol improved recovery of 
parasympathetic tone and decreased morning sympathetic predominance for 
 post-MI patients (73). The addition of metoprolol to ramipril-treated type 1 
diabetic patients with abnormal albuminuria was also shown to improve 
autonomic dysfunction. (74). 
Metformin 
Free fatty acids (FFAs) interfere with glucose metabolism (75).Under 
normal circumstances; FFAs are the main fuel source for the heart (76). 
Recently, it has been shown that the combination of TNF-  and 
hyperglycemia stimulated lipolysis with a consequential increase in FFAs and 
induced insulin resistance (77). Decreased activation of the parasympathetic 
nervous system increases lipolysis, thus resulting in an increased 
concentration of FFAs in the plasma (76). An increase in FFAs has been shown 
to affect the cardiovascular system through activation of the sympathetic 
nervous system in healthy subjects (78), as well as in individuals with type 2 
diabetes (79). Recently, it was demonstrated that overweight type 2 diabetic 
patients had metformin-related decreases in FFAs and insulin resistance that 
were associated with improved sympatho-vagal balance80. 
Other Drugs: those that supplement adrenergic activity (midodrine) 
Medications that expand the plasma volume (fludrocortisone)), Enhancement 
of ganglionic transmission via the use of pyridostigmine (inhibitor of 
acetylcholinesterase) Octreotide- an somatotropin release-inhibiting hormone 
analog). 
                                      
 
 
AIM OF THE STUDY 
 
1. To determine the prevalence of cardiac autonomic neuropathy in  
type 2 diabetes mellitus patients. 
2.  To examine the relationship between autonomic dysfunction and 
age, sex, known duration of the disease, glycemic control and 
body mass index. 
3. To establish the relation between diabetic retinopathy, peripheral 
neuropathy and diabetic cardiac autonomic neuropathy. 
 
 
 
 
 MATERIALS AND METHODS 
MATERIALS: 
 The study included fifty patients with type 2 diabetes 
mellitus attending the outpatients department of Medicine and Diabetology of 
Government Rajaji hospital .Thirty age and sex matched healthy volunteers 
were chosen as controls. Informed consent was obtained from each patient 
and control subject. 
 A careful history was taken from each persons and 
stress was laid on duration of illness as well as the symptoms suggestive of 
autonomic nervous systems dysfunction, diabetic retinopathy, and peripheral 
neuropathy 
 Detailed examination of both control and cases were 
done to find out the presence of peripheral neuropathy, diabetic retinopathy 
and other factors enabling them to include or exclude in this study. 
SELECTION OF CASES 
 Cases included in this study were selected as per the 
records available with them with treatment particulars. Duration the disease, 
body mass index ,current blood sugar values were taken in to consideration. 
Duration of the study :    1 year 
  
EXCLUSION CRITERIA FOR CASES 
1.Presence of coronary artery disease, cardiomyopathy, arrhythmias, patients 
on drugs like beta blockers, anti arrhythmics. 
2.Presence of diabetic kidney disease, chronic renal failure. 
3.Presence of liver disease. 
4.Presence of chronic obstructive pulmonary disease. 
5.Presence of central or peripheral nervous system disease other than due to 
diabetes mellitus like CVA, leprosy. 
6.Presence congestive cardiac failure, severe volume overload 
7.Presence of electrolyte abnormality like hypokalemia, hyponatremia 
8.Presence of any other disease that affects the ANS like hypothyroidism, 
amyloidosis, systemic lupus erythematosis, multiple myeloma..etc 
SELECTION OF CONTROLS 
 Age and sex matched healthy controls who were non 
diabetic, normotensive with normal blood sugar and renal function tests 
having normal resting electrocardiogram were selected for the study. 
 METHODS 
               Five  standard cardio vascular autonomic reflex tests 
(Ewings et al,1970)(4) which  assess the integrity of autonomic nervous 
systems were done using continuous ECG monitoring with 8-CHANNEL 
PSYCO-PHYSIOPAC. First three tests assessed parasympathetic system 
and the rest two assessed sympathetic function.  
1.HEART RATE RESPONSE TO DEEP BREATHING  
 The patient is made sit quietly and breathe at the rate 
of six breaths per minute for one minute. An ECG is recorded throughout the 
period of deep breathing, with marker to indicate the onset of each inspiration 
and expiration using 8-CHANNEL PSYCO-PHYSIOPAC. The maximum and 
minimum heart rate during each breathing cycle is measured. The results  is 
then expressed as the mean of the difference between maximum and 
minimum heart rate for the six measured cycles. 
2. HEART RATE RESPONSE TO VALSALVA MANOEUVRE 
 The patient is asked to blow in to the rubber tubing 
of the sphygmomanometer and hold it at pressure of 40 mm of mercury for 
15seconds while continuous ECG was recorded. Then the patient was asked 
to breathe normally with continuous ECG monitoring. The maneuver is 
 performed thrice ,with one minute interval in between them. The result in the 
valsalva ratio, which is calculated  as the ratio of the  maximum heart rate 
during the release phase to the minimum  heart rate during the straining phase 
.3. IMMEDIATE HEARTRATE RESPONSE TO STANDING 
   The test is performed with the patient lying quietly, while a 
continuous ECG is being recorded. The patient is asked to standup and the 
point at the start of standing is marked on the ECG paper. The shortest RR 
interval at or around the 15th beat and the longest RR interval at or around the 
30th beat after standing are measured .The result is expressed as the ratio of 
RR interval of thirtieth to fifteenth beat (30:15 ratio)  
4.BLOOD PRESSURE RESPONSE TO STANDING 
   Measuring patient’s blood pressure twice, once is at lying 
posture and the second is at standing posture performs this test. The standing 
blood pressure is taken after an interval of three minutes of standing. The 
blood pressure response is the difference in systolic pressure on lying and on 
standing. The test is repeated thrice and the average of 3 values is taken into 
account. 
 
 
  
5.  BLOOD PRESSURE RESPONSE TO SUSTAINED HANDGRIP 
  The maximum voluntary contraction of hand is determined and the hand 
grip is maintained at one third of the maximum up to three minutes using 
dynamometer. The result is expressed as the difference between the highest 
diastolic blood pressure during the hand grip and the normal diastolic blood 
pressure before the hand grip. 
                          The results of each of the above five tests are classified into 
three separate groups based on the severity of abnormality detected, and each 
of them is given a definite point as described by Bellavere et al.(116) 
 The total points from each of these five tests are added together and the 
cardiac autonomic neuropathy score, (CAN score) categorized as follows: 
CAN score 0 (total points 0), CAN score 1 (points 0.5–1.5), CAN score 2 
(points 2–3), and CAN score 3 (points >3.5). CAN is considered absent, 
early, definite or severe if the CAN scores are 0, 1, 2 or 3, respectively. 
 
 
 
 
 TABLE:1 DETERMINATION OF CAN SCORE 
Autonomic function test  Points 
1 Heart rate variability on deep breathing  
    >15 beats/min 0 
   11-15 beats/min        1/2 
   <11 beats/min 1 
2. Postural hypotension      (fall in systolic blood pressure)  
    <10 mm Hg 0 
    11-29 mm Hg 1/2 
   >30 mm Hg  1 
3. Valsalva ratio (longest RR interval: shortest RR interval)  
  >1.2  0 
  1.2–1.10  1/2 
  <1.10  1 
4. Heart rate variability on standing(30:15)  
   >1.04 0 
   1.01-1.03  1/2 
   <1   1 
5. Increase in diastolic blood pressure during sustained 
handgrip 
 
  >15 mm Hg  0 
  15–10 mm Hg  1/2 
  <10 mm Hg  1 
 OTHER TESTS DONE ON THE PATIENTS 
 Each participant is examined for the presence or absence of peripheral 
neuropathy during the neurological examination by testing for abnormal pin-
prick sensations in the limbs using monofilament (10 gms/5.07), abnormality 
of  vibration sense in the foot and hands using tuning fork-128Hz and the 
Achille’s tendon reflex. All patients were examined for diabetic retinopathy 
using indirect ophthalmoscope. 
BIOCHEMICAL INVESTIGATIONS 
 Blood is drawn from all patients under recommended ideal conditions to 
determine the fasting and post prandial blood sugar ,serum electrolyte, blood 
urea, serum creatinine and lipid profile. Urine of the patients was tested for 
presence of microalbuminuria and patients with elevated renal parameters or 
with albuminuria were excluded from the study 
STATISTICAL ANALYSIS 
 Statistical analysis of data was done using SPSS Statistics Software 
version 17.0 
 
 
 DEFINITIONS 
Known Duration of The Diseases 
 Patients with known duration of diabetes up to 5 years and those with 
duration of disease more than 5 years were classified in to two groups for 
study purposes. 
Body Mass Index 
 The cut off value of Body Mass Index was taken as 25 kg /m2 .Those 
with BMI above 25 and those with BMI below 25 are classified separately. 
Glycemic Control 
 Patients whose blood sugar values of either fasting blood sugar more 
than 130 mg/dl or postprandial blood sugar more than 180 mg/dl considered 
as having poor glycemic control(1). Others are considered to be having good 
glycemic control. 
Peripheral neuropathy 
 Absence of both ankle reflexes taken as absent and abnormality of any 
one of the each monofilament test in six sites in each foot taken as abnormal. 
Impaired vibration sense in any of the foot or hand taken as absent vibration 
sense. 
 Retinopathy 
 Patients are classified in to having normal fundus,non proliferative 
retinopathy, and proliferative retinopathy on examining  the dilated fundus 
depends on the appearance of the fundus on indirect ophthalmoscopy. 
CAN SCORE: a patient/control is considered to be having cardiac 
autonomic neuropathy if he/she scores  two or more than two. If  they  score 
less than two ,they are considered to be having no cardiac autonomic 
neuropathy. 
 
 
 
 
 
 
 
 
 
  
RESULTS AND ANALYSIS 
Composition of Study Population 
The study population consists of 50 cases and 30 age and sex matched 
healthy controls. 
Cases: 
 Among 50 cases ,27 (54%) were females and 23(46%) were males. 
Controls: 
 Among controls 15(50%) were males and 15(50%) were females. 
1.Prevalence of Cardiac autonomic neuropathy 
 In the present study, 31 (62%)out of 50 type 2 Diabetic patients having 
evidence of cardiac autonomic neuropathy. 
 
 
 
 
  
2.CAN and age 
 The present study population included patients between age groups of 41 
and 71.In this study CAN was more common in the age group of 61-70. 
Nintey one percentage (91.7% ) of the age group of 61-70 showed CAN, but 
only 47.4%of the age group 41-50 showed the evidence of CAN. Prevalence 
of the cardiac autonomic neuropathy increased with age group in this study 
population.   
TABLE NO: 2   CAN SCORE AND AGE 
 
 
 
 
 
 
 
 
 
Age CAN SCORE 
 Negative Positive Total 
41-50 Count 10 9 19 
% 52.6% 47.4% 100.0% 
51-60 Count 8 11 19 
% 42.1% 57.9% 100.0% 
61-70 Count 1 11 12 
% 8.3% 91.7% 100.0% 
TOTAL Count 19 31 50 
% 38.0% 62.0% 100.0% 
Pearson chi-
square 
value Df Asymp. Sig. (2-sided) 
6.345 2 0.042 
  
3.SEX  DISTRIBUTION AND CAN SCORE 
TABLE NO:3 SEX DISTRIBUTION AND CAN SCORE. 
 
SEX 
CAN SCORE 
 Negative Positive Total 
 
MALE 
Count 11 16 27 
% 40.7% 59.3% 100% 
 
FEMALE 
Count 8 15 23 
% 34.8% 65.2% 100.0% 
TOTAL Count 19 31 50 
% 38.0% 62.0% 100.0% 
Pearson 
chi-
square 
 value Df Asymp. Sig. (2-sided) 
6.345 2 0.665 
 
 In the present study, 16 out of 27 (59.3% ) males and 15 of 23 (65.2%) 
females showed evidence of cardiac autonomic neuropathy, which was not 
significant. (p=0.665). 11 out of 27 (40.7%)males and 8 out of 23 
(34.8%)females did not have cardiac autonomic neuropathy. This showed sex 
was not a major determinant for the prevalence of cardiac autonomic 
neuropathy. 
 
 
  
 
4. CAN AND KNOWN DURATION OF THE DISEASE  
 There were 23 cases of more than 5 years of diabetes, of which 20 cases 
having cardiac autonomic neuropathy. Out of 27 cases of less than 5 years of 
diabetes only 11 cases showed cardiac autonomic neuropathy, which was 
significant.(p= 0.001) 
TABLE NO4:CAN SCORE AND  KNOWN DURATION OF THE DISEASE 
 
 
 
 
DURATION 
CAN SCORE 
 Negative Positive Total 
 
<=5 
Count 16 11 27 
%withinDuration 59.3% 40.7% 100% 
 
>5 
Count 3 20 23 
%withinDuration 13.0% 87.0% 100.0% 
TOTAL Count 19 31 50 
%withinDuration 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
11.260 1 0.001 
  
5. BMI and CAN: 
TABLE NO:5.BMI AND CAN SCORE 
BMI 
 
CAN SCORE 
 Negative Positive Total 
NORMAL Count 9 9 18 
%withinBMI 50.0% 50.0% 100% 
OBESE Count 10 22 32 
%withinBMI 31.3% 68.8% 100.0% 
TOTAL Count 19 31 50 
%withinBMI 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
1.719 1 .190 
 
In the present study, 9 of out 18 patients(50%) of having BMI less than 
25 and 22 out of 32 patients (68.8%) of having BMI more than 25 showed 
presence of cardiac autonomic neuropathy, which was not significant          
(p= .190). 
 
 
  
 
6.  CAN AND GLYCEMIC CONTROL 
    This study showed 6 of 27 patients (35.3%) having good glycemic control 
had CAN and 25 of 33 patients (75.8%) having poor glycemic control had 
evidence of CAN, which was significant (p= .005) 
TABLE NO:6 CAN AND GLYCEMIC CONTROL 
 
 
 
 
 
 
glycemic 
control 
CAN SCORE 
 Negative Positive Total 
GOOD Count 11 6 17 
%within Gly_Cont 64.7% 35.3%% 100% 
POOR Count 8 25 33 
%within Gly_Cont 24.2%% 75.8%% 100.0% 
TOTAL Count 19 31 50 
%withinGly_Cont 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
7.719 1 .005 
  
7.FUNDUS AND CAN  
TABLE NO7:FUNDUS AND CAN SCORE 
 
    8 out of 8 patients (100%)having proliferative retinopathy showed cardiac 
autonomic neuropathy, while 9  out of11 patients (81.8%)of non proliferative 
retinopathy showed presence of cardiac autonomic neuropathy. Only 14 of 31 
patients having normal fundus showed cardiac autonomic 
neuropathy.(45.2%),which was statistically significant(p = .005). 
 
FUNDUS 
 
CAN SCORE 
 Negative Positive Total 
NORMAL Count 17 14 31 
% within Fundus 54.8% 45.2% 100% 
NPDR Count 2 9 11 
% within Fundus 18.2% 81.8% 100.0% 
PDR Count 0 8 8 
% within Fundus  100.0% 100.0% 
TOTAL Count 19 31 50 
%withinGly_Cont 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
10.468 2 .005 
  
8. ANKLE REFLEX and CAN SCORE 
   This study showed 29 out of 42 patients (69%) having absent ankle reflexes 
had cardiac autonomic neuropathy. Only two patients out of 8(25%) having 
ankle reflexes had cardiac autonomic neuropathy. Six out of eight 
patients(75%)having ankle reflexes did not have cardiac autonomic 
neuropathy, which was statistically significant.(p=0.019) 
TABLE NO:8 ANKLE REFLEX AND CAN SCORE 
 
 
 
ANK_REF CAN SCORE 
 Negative Positive Total 
ABSENT Count 13 29 42 
% within Ank_Ref 31.0% 69.0% 100% 
PRESENT Count 6 2 8 
% within Ank_Ref 75.0% 25.0% 100.0% 
TOTAL Count 19 31 50 
%withinAnk_Ref 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
5.534 1 .019 
  
9.VIBRATION SENSE AND CAN SCORE 
TABLE NO:VIBRATION SENSE AND CAN SCORE 
  
          This study showed 16 patients of 17 (94.1%) of absent perception of 
vibration sense had cardiac autonomic neuropathy, and only 15 of 33 
patients(45.5%) with perception of vibration sense had cardiac autonomic 
neuropathy, which was statistically significant(p = .001) 
 
 
VIBRATION 
TEST 
CAN SCORE 
 Negative Positive Total 
ABSENT Count 1 16 17 
% within Vibr_Test 5.9% 94.1% 100% 
PRESENT Count 18 15 33 
% within Vibr_Test 54.5% 45.5% 100.0% 
TOTAL Count 19 31 50 
% within Vibr_Test 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
11.278 1 .001 
  
 11.  MONOFILAMENT TEST AND CAN SCORE 
 This study showed 5 out of 21 (23.8%)patients with 
normal monofilament tests had cardiac autonomic neuropathy. 26 of 29 
(89.7%) patients with abnormal monofilament tests showed evidence of 
cardiac autonomic neuropathy, which was statistically significant(p=0 .0001) 
 
TABLE NO:10 MONOFILAMENT TEST AND CAN SCORE 
 
 
 
 
MONOFILAMENT CAN SCORE 
 Negative Positive Total 
NORMAL Count 16 5 21 
% within Mon_Fila 76.2% 23.8% 100% 
ABNORMAL Count 3 26 33 
% within Mon_Fila 10.3% 89.7% 100.0% 
TOTAL Count 19 31 50 
% within Mon_Fila 38.0% 62.0% 100.0% 
Pearson chi-square  value Df Asymp. Sig. (2-sided) 
11.278 1 .0001 
  
 
11.RESTING HEART RATE AND CAN  SCORE 
TABLE NO:11 RESTING HEART RATE AND CAN SCORE 
  
 Thirty (30) out of 49patients (61.2%) having resting 
heart rate less than 100 showed presence of cardiac autonomic neuropathy. 
Only one patients with resting heart rate more than 100 showed presence of 
cardiac autonomic neuropathy, which was statistically insignificant (p=0.429) 
 
 
Resting heart rate                                           CAN SCORE  
 Negative Positive Total 
<100 Count 19 30 49.0% 
% within restin heart rate 38.8% 61.2% 100% 
ABNORMAL Count 0 1 1 
% within resting heart rate 0% 100% 100% 
TOTAL Count 19 31 50 
% within resting heart rate 38.0% 62.0% 100.0% 
Pearson chi-square  value Df Asymp. Sig. (2-sided) 
.625 1 .429 
 12.VALSALVA RATIO AND CAN SCORE 
TABLE NO:12 VALSALVA RATIO AND CAN SCORE 
 
 In this study 16 of 16 (100%) patients having 
valsalva ratio less than 1.10 showed presence of cardiac autonomic 
neuropathy.15 of 21 patients( 71.4%) having valsalva ratio between 1.10 and 
1.20 showed evidence of cardiac autonomic dysfunction.13 patients having 
ratio more than 1.2 showed no evidence of cardiac autonomic neuropathy. So 
valsalva ratio appeared to be a good predictor of cardiac autonomic 
neuropathy.(p= 0.0001). 
VALSALVA 
RATIO 
                                          CAN SCORE  
 Negative Positive Total 
<1.10 Count 0 16 16 
% within Vals_Ratio 0 100 % 100% 
1.10-1.20 Count 6 15 21 
% within Vals_Ratio 28.6% 71.4% 100.0% 
>1.20 Count 13 0 13 
% within Vals_Ratio 100.0% .0% 100.0% 
Total Count 19 31 50 
% within Vals_Ratio 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
11.278 1 .0001 
 13.DIASTOLIC BLOOD PRESSURE DIFFERENCE AND CAN 
SCORE 
TABLE NO:14.DIASTOLIC BP  DIFFERENCE AND CAN SCORE 
 This study showed 14 of 17 patients (82.4%) of 
having diastolic blood pressure difference less than 10 during isometric 
exercise showed presence of cardiac autonomic neuropathy.14 of 21 patients 
( 66.7%) with diastolic rise in blood pressure between 15-10 showed the 
presence  of cardiac autonomic neuropathy. Only 3 of 12 patients (25%) 
having diastolic blood pressure rise more than 15 during isometric exercise 
showed evidence of cardiac autonomic neuropathy. It showed rise of diastolic 
blood pressure during isometric exercise was a good predictor of cardiac 
autonomic neuropathy.(p=0 .006) 
DIASTOLIC BP 
DIFFERENCE 
                                          CAN SCORE  
 Negative Positive Total 
<10 Count 3 4 7 
% within DBP_Diff 17.6% 82.4% 21% 
10-15 Count 7 14 21 
% within DBP_Diff 33.3% 66.7% 100.0% 
>15 Count 9 3 12 
% within DBP_Diff 75.0% 25.0% 100.0% 
Total Count 19 31 50 
% within DBP_Diff 38.0% 62.0% 100.0% 
Pearson chi-square  value Df Asymp. Sig. (2-
sided) 
10.156 2 .006 
  
14. HEART RATE VARIABILITY AND CAN SCORE 
TABLE NO:14. HEART RATE VARIABILITY AND CAN SCORE 
 
 This study showed 21 of 23 patients (91.3%) having 
heart rate variability less than 10 during deep breathing had evidence of 
cardiac autonomic neuropathy which is significant.(p=.0001). 8 out of 23 
patients (34.8%) having heart rate variability between 10-15 showed  
evidence of cardiac autonomic neuropathy. Only two of four patients (50%) 
having heart rate variability more than 15 showed presence of cardiac 
autonomic neuropathy. 
 
HEART RATE 
VARIABILITY 
                                          CAN SCORE  
 Negative Positive Total 
<10 Count 2 21 23 
% within HR_Diff 8.7% 91.3% 21% 
10-15 Count 15 8 23 
% within HR_Diff 65.2% 34.8% 100.0% 
>15 Count 2 2 4 
% within HR_Diff 50.0% 50.0% 100.0% 
Total Count 19 31 50 
% within HR_Diff 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
15.860 2 .0001 
  
15.   30:15  RR INTERVAL RATIO AND CAN SCORE. 
TABLE NO: 16    30:15 RR INTERVAL RATIO AND CAN SCORE 
 
 In this study 14 patients of 14 (100%) having  
abnormal (<1) 30:15 ratio showed presence of cardiac autonomic neuropathy. 
Only 17 of 36 patients having normal (>1.04) 30:15 ratio showed presence of 
cardiac autonomic neuropathy. So the presence of abnormal 30:15 ratio was 
statistically significant in predicting cardiac autonomic neuropathy.             
(p= is .001) 
RR INTERVAL 
RATIO(30:15 
ratio) 
CAN SCORE 
 Negative Positive Total 
ABNORMAL 
( < 1) 
Count 0 14 14 
% within RR_Ratio 0% 100.0% 100.0% 
NORMAL 
(  > 1.04) 
Count 19 17 36 
% within RR_Ratio 52.8% 47.2% 100.0% 
Total Count 19 31 50 
% within RR_Ratio 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
11.918 1 .001 
  
16.  SBP fall and CAN SCORE 
TABLE NO:17. SYSTOLIC BP FALL AND CAN SCORE 
  
 This study showed 16 of 33 patients(48.5%) with 
systolic blood pressure fall less than 10 during standing had cardiac 
autonomic neuropathy.15 of 17 patients(88.2%) with systolic blood pressure 
fall between 11-30 showed evidence of cardiac autonomic neuropathy, which 
was statistically significant(p=0.006). In the study group nobody showed a 
systolic BP fall of more than 30mm of mercury during standing. 
 
 
 
SYSTOLIC BP 
FALL 
                                          CAN SCORE  
 Negative Positive Total 
<= 10 Count 17 16 33 
% within SBP_Fall 51.5% 48.5% 100.0% 
11-30 Count 2 15 17 
% within SBP_Fall 11.8% 88.2% 100.0% 
Total Count 19 31 50 
% within SBP_Fall 38.0% 62.0% 100.0% 
Pearson chi-
square 
 value Df Asymp. Sig. (2-sided) 
7.525 1 .006 
 DISCUSSION 
The present study includes 50 patients of type 2 diabetes mellitus, with 
30 controls whose age and sex  is  matched  that of study group .  
           Takebayashi et al, studied 60 patients and Pourmoghaddas104 et al 
studied 200 patients. 
1.Prevalence of Cardiac autonomic neuropathy 
  In the present study, Cardiac autonomic neuropathy is observed 
in 31 patients of type 2 diabetes mellitus ( 62% ). 
 Jeyarajah 102R et al observed 46.2% prevalence and Ziegler et al 
observed 34.3% prevalence. Depending on the tests and criteria used, and on 
the patients cohorts studied, the prevalence shows variation between the 
studies. In 2008 Pappachan et al(6) found that the prevalence of cardiac 
autonomic neuropathy among type 2 DM patients was 60% in South Indian 
population.  Mehta(7) et al published an Indian study showing 57.5% of 
prevalence of cardiac autonomic neuropathy in type 2 DM patients.  
2. Cardiac Autonomic neuropathy and age 
 In this study CAN is more common in the age group of 61-70. 
Ninteyone percentage (91.7%) of patients of the age group of 61-70 shows 
CAN, but only 47.4%of the age group 41-50 shows the evidence of CAN. 
 Prevalence of the cardiac autonomic neuropathy increases with age group in 
this study population. The same observation was made by Valensi(5) and 
Jeyarajah102 et al. Advancing age is a strong risk factor for diabetic 
neuropathy, independent of the duration of diabetes mellitus and glycemic 
control. The prevalence of diabetes mellitus increases markedly with age. 
Furthermore, several biological changes occurring during the aging process 
may account for the facilitating effect of age on diabetic neuropathy. These 
include an increase in the production of advanced glycosylation end-products 
(AGEs), a defect in the polyol pathway, nerve vascular alterations and 
impaired resistance to oxidative stress. The clinical diagnosis of diabetic 
neuropathy is often difficult in elderly patients. The relationship between 
symptoms and neuropathy and that between neuropathy and diabetes mellitus 
are more difficult to ascertain in elderly patients due to age-related changes in 
the peripheral and autonomic nervous system and associated diseases 
frequently encountered in this population. Clinical complications of diabetic 
neuropathy in the elderly are often severe. Early detection is required, as it is 
the most effective way to avoid or postpone debilitating complications. 
Belmin J, Valensi P(5) et al  also found that severity of cardiac autonomic 
neuropathy increases with advancing age.In 1989 Nobutoshi Kuroda117 et al 
published a study proving the autonomic function is related to age. They 
 proved  that autonomic function of young diabetic patient  corresponds to that 
of old non diabetic in terms of cardiac beat to beat variation. 
3. Cardiac Autonomic Neuropathy And Sex    
  In the present study, 16 0f 27  (59.3% ) females and 15 of 23 (65.2%) 
males show evidence of cardiac autonomic neuropathy, which is 
insignificant.(p=0.665). This shows  sex is not a major determinant for the 
prevalence of cardiac autonomic neuropathy. In the DCCT(38) trial presence 
of autonomic neuropathy correlated with male sex. Jaffe (8) et al showed male 
sex to be predominantly affected in cardiac autonomic neuropathy. May et al 
showed significant association of female sex with autonomic neuropathy. 
Hence   larger numbers of trial are needed to determine the prevalence of 
cardiac autonomic neuropathy among either sex particularly in relation to 
Indian ethnicity. 
4.Cardiac autonomic neuropathy and Duration of the disease 
 There are 23 cases with more than 5 years of diabetes of which 
20(87%) cases have cardiac autonomic neuropathy. Out of 27 cases with less 
than 5 years of diabetes ,only 11 cases (40.7%) show cardiac autonomic 
neuropathy, which is significant. (p=.001). Valensi(5) et al found that 
autonomic abnormality tests correlated significantly with duration of the 
disease. In 2008 Pappachen(6) et al established a significant correlation 
 between cardiac autonomic neuropathy and duration of the disease.(odds 
ratio-7.2). 
5.Cardiac autonomic neuropathy and BMI 
 Present study shows  9 out of 18 patients (50%) having BMI less 
than 25 and 22 of 32 patients (68.8%) having BMI more than 25 show 
evidence cardiac autonomic neuropathy, which is insignificant. (p=0.190). 
Hence our study does not show any correlation between BMI and cardiac 
autonomic neuropathy. This is in accordance with the study reports of Chen 
H.T  et al in 2008. 
6.Cardiac autonomic neuropathy and Glycemic control 
 This study shows  6 out  of 27 patients (35.3%)having good 
glycemic control have  CAN and 25out  of 33 patients (75.8%) having good 
glycemic control have CAN, which is significant (p=0.005). Mustonen() et al 
reported the similar results in 4 year follow up study of 32 individuals with 
poor glycemic controls. In 1990, Vegilo.M et al published a study proving 
autonomic neuropathy correlated  with metabolic control of diabetes. The 
results from the DCCT Trial showed  that intensive glycemic treatment can 
prevent the development of abnormal heart rate variation and slow the 
deterioration of autonomic dysfunction over time(Ziegler 1994). 
 7.Cardiac autonomic neuropathy and FUNDUS 
 In this study all patients having proliferative retinopathy show 
presence of cardiac autonomic neuropathy, while 9 of 11 patients (81.8%)of 
non proliferative retinopathy show presence of cardiac autonomic 
neuropathy, which is statistically significant(p=0 .005).Only 14 of 31 patients 
having normal fundus show cardiac autonomic neuropathy.(45.2%) Thus 
severity of retinopathy correlated with the degree of cardiac autonomic 
dysfunction. The study result establishes the important association between 
cardiac autonomic neuropathy and diabetic retinopathy. S.E SMITH et(9) al, 
and HELENA SCHMID(10) et al showed similar correlation between grade of 
diabetic retinopathy and cardiac autonomic dysfunction in their studies . 
8.Cardiac Autonomic Neuropathy And Peripheral Neuropathy. 
                  This study shows 29 out of 42(69%). patients having absent ankle 
reflexes had   cardiac autonomic neuropathy. Only 2 out of 8 patients (25%) 
having ankle reflexes show presence of cardiac autonomic neuropathy, which 
is statistically significant (p=0.019). Six of eight patients (75%) having ankle 
reflexes do not show evidence cardiac autonomic neuropathy. Hence it is a 
good predictor of severity of cardiac autonomic neuropathy.  
            In this study, 16 patients out of 17 (94.1%) having  absent perception 
of  vibration sense show cardiac autonomic neuropathy, and only 15 of 33 
 patients(45.5%) with perception of vibration sense show cardiac autonomic 
neuropathy, which is statistically significant(p-value is .001).  
              This study also shows 5 out of 21 (23.8%)patients with normal 
monofilament tests have cardiac autonomic neuropathy. 26 out of 29 
(89.7%)patients with abnormal monofilament tests have cardiac autonomic 
neuropathy, which is again  statistically significant (p=0 .0001). 
                    Thus patient diagnosed to have peripheral neuropathy by clinical 
examination should be screen for cardiac autonomic neuropathy. NEVZAT 
(110) et al in 2006 found that severity of cardiac autonomic neuropathy is 
associated with increased prevalence of other micro vascular complications. 
NEVZAT et(110) al in their study showed that there was no significant 
difference regarding the prevalence of peripheral neuropathy diagnosed by 
neurological examination and scintigraphic measurement of gastric and 
bladder emptying time ,or by EMG .In 2008 Pappachan(6) et al published a 
study establishing significant association between cardiac autonomic 
neuropathy and peripheral neuropathy(p<.001). 
9.Cardiac autonomic neuropathy and Autonomic function tests 
                In this study, 30 out of 49patients (61.2%) having resting heart rate 
less than 100 show presence of cardiac autonomic neuropathy. Only one 
patient with resting heart rate more than 100 shows presence of cardiac 
autonomic neuropathy. This study shows that resting tachycardia is not a 
 good predictor of cardiac autonomic dysfunction. S.E SMITH, S.A.SMITH (9) 
and P.M BROWN reported that resting tachycardia is an unreliable marker of 
cardiac autonomic neuropathy. 
                  There were five non invasive cardiovascular reflex tests used to 
assess the cardiac autonomic neuropathy. They were heart rate variation to 
deep breathing, heart rate variation to valsalva maneuver, postural 
tachycardia index, systolic blood pressure response to standing and diastolic 
blood pressure response to hand grip. First 3 tests used to assess the  
parasympathetic system and 2 tests for the sympathetic system. In this study 
heart rate variation to deep breathing (p=0.0001),heart rate variation to 
valsalva maneuver expressed by valsalva ratio (p=0.0001) are the better 
predictors of assessing cardiac autonomic neuropathy compared to other tests. 
Jeyarajah(102) et al reported that of all the tests performed ,heart rate response 
to deep breathing was the commonest to become abnormal. Strobescue(109) et 
al in 2002 showed that changes in heart rate during deep inspiration–
expiration remains the preferable tests according to its sensitivity, specificity 
and predictive value. 
               Diabetes Mellitus is an old disease of human being and autonomic 
dysfunction involving virtually all the body system is an established 
complication. Cardiac autonomic neuropathy is the most frequent and 
clinically important form of diabetic autonomic neuropathy. .Cardiovascular 
 dysfunction assumes maximum importance because it leads to silent 
infarction, intractable arrhythmias and sudden cardiac death. Cardiac 
autonomic neuropathy is associated with increased frequency of other micro 
vascular complications. 
                       A group of non invasive tests have been used for the diagnosis 
of cardiac autonomic neuropathy. These tests although sensitive and 
reproducible, are time consuming and are not practical screening methods in 
crowded diabetic clinics. As cardiac autonomic neuropathy is common in 
diabetes, and it is associated with known duration of the disease, control of  
hyperglycemia. So early detection of diabetes and assessing the risk factors 
and controlling modifiable risk factors are important cornerstone of 
preventing its complication.  
                    The severity of other micro vascular complications like diabetic 
retinopathy and peripheral neuropathy parallel the severity of cardiac 
autonomic neuropathy. Examination of dilated fundus, ankle reflexes, 
monofilament tests, vibration tests are simple tests performed in routine out 
patient clinics. This study showed that patients with proliferative retinopathy, 
and  peripheral neuropathy also had cardiac autonomic neuropathy.  
 So  fundus examinations, clinical tests  like checking 
ankle reflexes, monofilament tests, vibration tests are predictors of the 
severity of cardiac autonomic neuropathy. 
                                           
SUMMARY 
                  The study “Cardiac Autonomic Neuropathy in Type 2 Diabetes 
Mellitus patients” was a case control study conducted on patients visiting 
outpatient department of Diabetes clinic of Government Rajaji Hospital 
Maduari.50 patients with type 2 Diabetes Mellitus and 30 healthy controls 
were included in this study. Selected patients and controls underwent clinical 
and biochemical evaluation including Ewing’s Reflex Tests using 8 Channel 
PSYCOPHYSIOPAC. They were also subjected to clinical examination for 
peripheral neuropathy, fundus examination, fasting and postprandial blood 
sugar estimation, and BMI calculation. It was observed that prevalence of 
cardiac autonomic neuropathy is correlated with age, known duration of the 
disease, and glycemic control. There is no correlation of cardiac autonomic 
neuropathy with sex and body mass index. There is a significant correlation 
between the severity of retinopathy and degree of cardiac autonomic 
neuropathy. Presence of peripheral neuropathy is associated with increasing 
severity of cardiac autonomic neuropathy. Simple neurological examination 
like ankle reflexes, vibration sense and monofilament test helps to predict the 
presence and severity of cardiac autonomic neuropathy. 
 
  
 CONCLUSIONS  
 
• The prevalence of cardiac autonomic neuropathy is 62% in patients 
with type 2 Diabetes Mellitus. 
• The presence of cardiac autonomic neuropathy is directly related to the 
age, known duration of the disease and glycemic control. 
• There is no direct correlation between cardiac autonomic neuropathy, 
sex and body mass index. 
• The degree of diabetic retinopathy is associated with degree of cardiac 
autonomic neuropathy. 
• The prevalence of peripheral neuropathy increases as the severity of 
cardiac autonomic neuropathy increases in patients with type 2 
Diabetes Mellitus. 
• This study emphasizes the need for an early screening for peripheral 
neuropathy, retinopathy  and other micro vascular complications in 
Type 2 diabetes patients  and it reflects the severity of  cardiac 
autonomic neuropathy. 
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 PROFORMA 
CARDIAC AUTONOMIC NEUROPATHY IN  TYPE 2 DIABETES 
MELLITUS 
 
 
CASE NO:                                                                                                           DATE: 
OP     : 
NAME:-      
AGE:                              SEX: 
ADDRESS:     OCCUPATION: 
PHONE: 
 
SOCIO ECONOMIC STATUS: 
HISTORY OF ILLNESS: 
 
1KNOWN DURATION 
 
 
 
    TYPE  II DM           
 
2.PRESENT SYMPTOMS 
 
 
3.TREATMENT HISTORY 
 
PAST H/O:- 
 
HTN      TB      ASTHMA      LIVER DISEASE    
CAD      CVA      DYSLIPIDEMIA RENAL DISEASE 
 
FAMILY H/O:- 
DM           HTN       CAD             DYSLIPIDEMIA 
  
OTHER RELEVENT HISTORY              
             
 
MENSTRUAL H/O:- 
  
 
GENERAL EXAMINATION:- 
 
BUILT:                                                                          NOURISHMENT 
 
PALLOR                 ICTERUS                      CLUBBING                 EDEMA                         
 
CYANOSIS                 LYMPHADENOPATHY 
 
RESTING PULSE RATE:-            
   
BLOOD PRESSURE:  SUPINE 
 
           STANDING 
            
          DIASTOLIC BP:  Before isometric exercise:   
              After isometric exercise: 
RESPIRATORY RATE:  
TEMPERATURE: 
 
OTHER SYSTEMS:- 
CVS:                                                   
 
RESPIRATORY SYSTEM: 
  
 
 CNS: 
 
 HMF 
 
 CRANIAL NERVES 
 
           
 INVESTIGATIONS:- 
CBC: 
Hb          TC               
 DC                     
 ESR               
PLT.COUNT 
URINE R/E 
 
        ALB              SUG             
 CASTS                
 RBC 
 
 
RBS:                  Blood urea:               S.Creatinine:                      S.E-  Na+                                                
                                                                                             K+ 
  
FLP:  Total chol         LDL                HDL                       VLDL               TG  
          Ankle reflex 
right left 
  
          Dilated fundus 
right left 
  
           Vibration sense-128Hz 
 right left 
Hand   
Foot    
       MONOFILAMENT TEST 
right left 
                                 
  
   
LFT:  TBb/DBb                   T.pro                   S.ALB/GLOB                
SGPT/SGOT         ALP 
 
HBA1C 
 
ECG 
 
QTc: 
 
CXR: 
 
 
CONTINOUS ECG MONITORING 
 
1. R-R INTERVAL IN VALSALVA MANOUVRE 
   
                 On straining: 
    After straining:  
    Ratio: 
 
         
2. HEART RATE IN DEEP BREATHING: 
 
Resting heart rate before deep breathing: 
   Heart rate during deep breathing: 
3.HR RESPONSE TO STANDING  
  RR INTERVAL AT 30th  beat: 
  RR INTERVAL AT 15th beat:                        30:15 Ratio: 
 
OTHERS: (if any) 
CAN SCORE: ABSENT (0)  EARLY (1)  DEFINITE (2)  SEVERE (>3) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Autonomic function test Points Pt’point 
1 Heart rate variability on deep breathing   
   >15 beats/min 0  
11-15 beats/min        1/2  
  <11 beats/min 1  
2. Postural hypotension      (fall in systolic blood 
pressure) 
  
    <10 mm Hg 0  
   11-29 mm Hg 1/2  
   >30 mm Hg  1  
3. Valsalva ratio (longest RR interval: shortest RR 
interval) 
  
  >1.2  0  
  1.2–1.10  1/2  
  <1.10  1  
4. Heart rate variability on standing(30:15)   
   >1.04 0  
   1.01-1.03  1/2  
   <10 beats/min  1  
5. Increase in diastolic blood pressure during sustained 
handgrip 
  
  >15 mm Hg  0  
  15–10 mm Hg  1/2  
  <10 mm Hg  1  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG:1 PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS 
  
 
 
 
 
 
FIG:2.   NON PROLIFERATIVE DIABETIC RETINOPATHY 
FIG:3 PROLIFERATIVE DIABETIC RETINOPATHY 
 ECG MONITORING WITH 8‐CHANNEL PSYCO PHYSIOPAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
GRAPH‐1 Prevalence of  Cardiac  Autonomic Neuropathy 
  
 
 
 
 
 
 
 
GRAPH‐2 Age distribution and Cardiac  Autonomic Neuropathy score
  
 
 
 
 
 
 
GRAPH‐4   Duration and cardiac autonomic neuropathy score 
  
 
 
 
 
 
 
GRAPH‐3    Sex Distribution And Can
  
 
 
 
 
 
GRAPH‐5 :BMI and Cardiac  Autonomic Neuropathy Score
  
 
 
 
 
 
GRAPH‐6: Glycemic Control and Cardiac Autonomic Neuropathy Score 
  
 
 
 
 
 
 
 
GRAPH‐7: FUNDUS and Cardiac  Autonomic Neuropathy Score 
  
 
 
 
 
 
GRAPH‐8:Ankle Reflexes and Cardiac  Autonomic  
Neuropathy Score 
  
 
 
 
 
 
GRAPH‐9: Vibration Sense  and Cardiac  Autonomic Neuropathy Score
  
 
 
 
 
 
 
GRAPH‐10:.Monofilament Tests and Cardiac  Autonomic Neuropathy 
Score 
 
  
 
 
 
 
 
 
GRAPH‐11 :resting heart rate and Cardiac  Autonomic Neuropathy Score
  
 
GRAPH‐12: Heart Rate variability and Cardiac   
Autonomic Neuropathy Score 
 
 
 
    
 
  
GRAPH‐13 :Valsalva ratio and Cardiac  Autonomic Neuropathy Score 
 
 
 
 
  
 
GRAPH‐15:    30:15 RR interval ratio and Cardiac   
Autonomic Neuropathy Score 
 
 
 
 
 
  
 
GRAPH‐14:   DBP difference  and Cardiac  Autonomic Neuropathy Score 
 
 
 
 
 
  
GRAPH‐16:   Systolic BP fall  and Cardiac  Autonomic Neuropathy Score 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
